Remove tag new-england-journal-medicine
article thumbnail

Actualising the power of antibody-drug conjugates as cancer therapeutics

European Pharmaceutical Review

ANTIBODY-DRUG conjugates (ADCs) are therapeutic molecules designed as highly targeted medicines with the promise of changing the way we treat cancer and other diseases. tag ® , inspired by the unique features of microtubule biology and perfectly suited for DAR 2 and DAR 4 ADCs. cancer agent or disease-relevant toxin.

article thumbnail

Developing point-of-care CAR T manufacturing

European Pharmaceutical Review

In other words, the apheresis centres must become an integral part of the pharmaceutical production line with identical quality assurance and regulations, which is new and unpreceded for both sides. This is in addition to its considerable price tag. Journal of Hematology & Oncology. References Liu D. 2019;12(1).